In addition, results of a further study demonstrated that localized oncolytic infection abrogated resistance to systemic anti-PD-1 immunotherapy, through upregulating PD-L1 in tumor cells and eliciting a broad-range T-cell attack against the neoantigen [27]. Here, PDCD1 is linked to neoplasm.